Literature DB >> 27492073

Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.

H S Nguyen1, N Milbach2, S L Hurrell2, E Cochran3, J Connelly4, J A Bovi5, C J Schultz5, W M Mueller1, S D Rand2, K M Schmainda2,6, P S LaViolette7,6.   

Abstract

BACKGROUND AND
PURPOSE: Patients with recurrent glioblastoma often exhibit regions of diffusion restriction following the initiation of bevacizumab therapy. Studies suggest that these regions represent either diffusion-restricted necrosis or hypercellular tumor. This study explored postmortem brain specimens and a population analysis of overall survival to determine the identity and implications of such lesions.
MATERIALS AND METHODS: Postmortem examinations were performed on 6 patients with recurrent glioblastoma on bevacizumab with progressively growing regions of diffusion restriction. ADC values were extracted from regions of both hypercellular tumor and necrosis. A receiver operating characteristic analysis was performed to define optimal ADC thresholds for differentiating tissue types. A retrospective population study was also performed comparing the overall survival of 64 patients with recurrent glioblastoma treated with bevacizumab. Patients were separated into 3 groups: no diffusion restriction, diffusion restriction that appeared and progressed within 5 months of bevacizumab initiation, and delayed or stable diffusion restriction. An additional analysis was performed assessing tumor O6-methylguanine-DNA-methyltransferase methylation.
RESULTS: The optimal ADC threshold for differentiation of hypercellularity and necrosis was 0.736 × 10-3mm2/s. Progressively expanding diffusion restriction was pathologically confirmed to be coagulative necrosis surrounded by viable tumor. Progressive lesions were associated with the worst overall survival, while stable lesions showed the greatest overall survival (P < .05). Of the 40% of patients with O6-methylguanine-DNA-methyltransferase methylated tumors, none developed diffusion-restricted lesions.
CONCLUSIONS: Progressive diffusion-restricted lesions were pathologically confirmed to be coagulative necrosis surrounded by viable tumor and associated with decreased overall survival. Stable lesions were, however, associated with increased overall survival. All lesions were associated with O6-methylguanine-DNA-methyltransferase unmethylated tumors.
© 2016 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27492073      PMCID: PMC5161572          DOI: 10.3174/ajnr.A4898

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  35 in total

1.  Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas.

Authors:  T Sugahara; Y Korogi; M Kochi; I Ikushima; Y Shigematu; T Hirai; T Okuda; L Liang; Y Ge; Y Komohara; Y Ushio; M Takahashi
Journal:  J Magn Reson Imaging       Date:  1999-01       Impact factor: 4.813

2.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Authors:  Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

3.  Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria).

Authors:  Nikdokht Farid; Daniela B Almeida-Freitas; Nathan S White; Carrie R McDonald; Joshua M Kuperman; Abdulrahman A Almutairi; Karra A Muller; Scott R VandenBerg; Santosh Kesari; Anders M Dale
Journal:  J Neurooncol       Date:  2014-08-19       Impact factor: 4.130

4.  Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.

Authors:  Rahul N Sawlani; Jeffrey Raizer; Sandra W Horowitz; Wanyong Shin; Sean A Grimm; James P Chandler; Robert Levy; Christopher Getch; Timothy J Carroll
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

5.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Authors:  Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin
Journal:  Neuro Oncol       Date:  2014-01-15       Impact factor: 12.300

6.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.

Authors:  Martin H Cohen; Yuan Li Shen; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2009-11-06

8.  Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival.

Authors:  Daniel A Hamstra; Craig J Galbán; Charles R Meyer; Timothy D Johnson; Pia C Sundgren; Christina Tsien; Theodore S Lawrence; Larry Junck; David J Ross; Alnawaz Rehemtulla; Brian D Ross; Thomas L Chenevert
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544

9.  Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.

Authors:  Benjamin M Ellingson; Eunhee Kim; Davis C Woodworth; Helga Marques; Jerrold L Boxerman; Yair Safriel; Robert C McKinstry; Felix Bokstein; Rajan Jain; T Linda Chi; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak
Journal:  Int J Oncol       Date:  2015-02-11       Impact factor: 5.650

10.  Restriction-Spectrum Imaging of Bevacizumab-Related Necrosis in a Patient with GBM.

Authors:  Nikdokht Farid; Daniela B Almeida-Freitas; Nathan S White; Carrie R McDonald; Karra A Muller; Scott R Vandenberg; Santosh Kesari; Anders M Dale
Journal:  Front Oncol       Date:  2013-09-30       Impact factor: 6.244

View more
  29 in total

Review 1.  Advanced MRI Techniques in the Monitoring of Treatment of Gliomas.

Authors:  Harpreet Hyare; Steffi Thust; Jeremy Rees
Journal:  Curr Treat Options Neurol       Date:  2017-03       Impact factor: 3.598

Review 2.  MR-guided radiation therapy: transformative technology and its role in the central nervous system.

Authors:  Yue Cao; Chia-Lin Tseng; James M Balter; Feifei Teng; Hemant A Parmar; Arjun Sahgal
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

3.  Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer.

Authors:  Bang-Bin Chen; Yen-Shen Lu; Chih-Wei Yu; Ching-Hung Lin; Tom Wei-Wu Chen; Shwu-Yuan Wei; Ann-Lii Cheng; Tiffany Ting-Fang Shih
Journal:  Eur Radiol       Date:  2018-05-16       Impact factor: 5.315

4.  Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.

Authors:  Naveen Galla; Gloria Chiang; Shamik Chakraborty; Ranjodh Singh; A John Tsiouris; John Boockvar; Ilhami Kovanlikaya
Journal:  Neuroradiology       Date:  2017-03-25       Impact factor: 2.804

Review 5.  Conventional and advanced imaging throughout the cycle of care of gliomas.

Authors:  Gilles Reuter; Martin Moïse; Wolfgang Roll; Didier Martin; Arnaud Lombard; Félix Scholtes; Walter Stummer; Eric Suero Molina
Journal:  Neurosurg Rev       Date:  2021-01-07       Impact factor: 3.042

6.  Differentiation of residual/recurrent gliomas from postradiation necrosis with arterial spin labeling and diffusion tensor magnetic resonance imaging-derived metrics.

Authors:  Ahmed Abdel Khalek Abdel Razek; Lamiaa El-Serougy; Mohamed Abdelsalam; Gada Gaballa; Mona Talaat
Journal:  Neuroradiology       Date:  2017-12-07       Impact factor: 2.804

Review 7.  Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques.

Authors:  D J Leao; P G Craig; L F Godoy; C C Leite; B Policeni
Journal:  AJNR Am J Neuroradiol       Date:  2019-12-19       Impact factor: 3.825

Review 8.  Intracranial long-term complications of radiation therapy: an image-based review.

Authors:  Carrie M Carr; John C Benson; David R DeLone; Felix E Diehn; Dong Kun Kim; Kenneth W Merrell; Alex A Nagelschneider; Ajay A Madhavan; Derek R Johnson
Journal:  Neuroradiology       Date:  2021-01-04       Impact factor: 2.804

9.  Diagnostic Accuracy of Centrally Restricted Diffusion in the Differentiation of Treatment-Related Necrosis from Tumor Recurrence in High-Grade Gliomas.

Authors:  N Zakhari; M S Taccone; C Torres; S Chakraborty; J Sinclair; J Woulfe; G H Jansen; T B Nguyen
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-07       Impact factor: 3.825

Review 10.  An Update on the Approach to the Imaging of Brain Tumors.

Authors:  Katherine M Mullen; Raymond Y Huang
Journal:  Curr Neurol Neurosci Rep       Date:  2017-07       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.